{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:20:46Z","timestamp":1772234446738,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["Roche"],"award-info":[{"award-number":["Roche"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Retinitis pigmentosa (RP) and Choroideremia (CHM) are rare inherited retinal diseases (IRDs) that can lead to severe visual impairment or blindness. Despite different underlying genetic pathways, they have many progression patterns in common, first affecting the more peripheral retina and later advancing toward the central retina. Early symptoms of both diseases include night blindness, difficulty adjusting to changing levels of light, and difficulty seeing in poor contrast. This is followed by progressive loss of the peripheral visual field in daylight, and eventually blindness. Currently, hardly any studies based on interviews that describe symptom experience and impact exist. In this concept elicitation study, we conducted qualitative interviews to identify the symptoms experienced by RP (<jats:italic>n<\/jats:italic>\u2009=\u200912) and CHM (<jats:italic>n<\/jats:italic>\u2009=\u20095) patients, and to understand the impact of symptoms on patients\u2019 lives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 14 symptoms reported, poor night vision\/night blindness, difficulty seeing in bright light, and difficulty seeing in low\/dim light were experienced by all participants. Over 50% of participants in either condition reported difficulty adapting from bright to dark and vice versa, poor peripheral vision, poor contrast sensitivity, poor distance vision, and poor visual acuity. Symptoms had a significant impact on activities of daily living. Most commonly impacted were the ability to navigate and the use of digital screens (<jats:italic>n<\/jats:italic>\u2009=\u200917\/17, 100%) as well as physical functioning and work\/school-related activities (<jats:italic>n<\/jats:italic>\u2009=\u200916\/17, 94.1%). These impacts were often exacerbated by environmental factors. For instance, all participants reported this for navigation. Additionally, most participants (<jats:italic>n<\/jats:italic>\u2009=\u200913\/17, 76.5%) reported impacts on emotional well-being. Concept saturation was shown for the RP sample (<jats:italic>n<\/jats:italic>\u2009=\u200912) and the combined sample (<jats:italic>n<\/jats:italic>\u2009=\u200917), i.e., all concepts reported were spontaneously mentioned in the first 3 sets of interviews. This suggests that further interviews would be unlikely to yield any new symptom concepts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The patient interviews provided insight into the patient experience of RP and CHM and formed the basis for developing a combined conceptual model of RP and CHM disease experience, suitable to serve as basis for future patient reported and performance outcome measures. Testing in larger samples, especially in CHM, is recommended to further evaluate content validity of these preliminary findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03713-4","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T07:35:30Z","timestamp":1754897730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient experience in retinitis pigmentosa and Choroideremia\u2013 a concept elicitation study in 17 patients based on qualitative interviews"],"prefix":"10.1186","volume":"20","author":[{"given":"Elke","family":"Rometsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8624-2110","authenticated-orcid":false,"given":"Per-Olof","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mie","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhart","family":"Eule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Bachmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-1-40","volume":"1","author":"C Hamel","year":"2006","unstructured":"Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.","journal-title":"Orphanet J Rare Dis"},{"key":"3713_CR2","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.ophtha.2016.06.051","volume":"123","author":"KN Khan","year":"2016","unstructured":"Khan KN, Islam F, Moore AT, Michaelides M. Clinical and genetic features of choroideremia in childhood. Ophthalmology. 2016;123:2158\u201365.","journal-title":"Ophthalmology"},{"key":"3713_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/eye.2016.315","volume":"31","author":"M Prem Senthil","year":"2017","unstructured":"Prem Senthil M, Khadka J, Pesudovs K. Seeing through their eyes: lived experiences of people with retinitis pigmentosa. Eye. 2017;31:741\u20138.","journal-title":"Eye"},{"key":"3713_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/ng0592-109","volume":"1","author":"E-M Sankila","year":"1992","unstructured":"Sankila E-M, Tolvanen R, van den Hurk JAJM, Cremers FPM, de la Chapelle A. Aberrant splicing of the CHM gene is a significant cause of choroideremia. Nat Genet. 1992;1:109\u201313.","journal-title":"Nat Genet"},{"key":"3713_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/PROM.S162802","volume":"10","author":"T Braithwaite","year":"2019","unstructured":"Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston AK. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas. 2019;10:9\u201324.","journal-title":"Patient Relat Outcome Meas"},{"key":"3713_CR6","doi-asserted-by":"crossref","unstructured":"Thompson DA, Iannaccone A, Ali RR et al. (2020) Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium. Transl Vis Sci Technol 9:2.","DOI":"10.1167\/tvst.9.7.2"},{"key":"3713_CR7","unstructured":"FDA. (2022) Patient-Focused Drug Development: Methods to Identify What Is Important to Patients Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. In Services USDoHaH, editor."},{"key":"3713_CR8","doi-asserted-by":"publisher","first-page":"S865","DOI":"10.1016\/j.jval.2019.09.2460","volume":"22","author":"J Banhazi","year":"2019","unstructured":"Banhazi J, Williamson N, Bradley H, et al. PRO131 WHAT DO WE KNOW ABOUT PATIENT\u2019S AND CAREGIVERS\u2019 EXPERIENCE WHEN LIVING WITH THE HEREDITARY RETINAL CONDITION RETINITIS PIGMENTOSA? Value Health. 2019;22:S865.","journal-title":"Value Health"},{"key":"3713_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, Grimshaw JM. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25:1229\u201345.","journal-title":"Psychol Health"},{"key":"3713_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59\u201382.","journal-title":"Field Methods"},{"key":"3713_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. Int J Qualitative Methods. 2006;5:80\u201392.","journal-title":"Int J Qualitative Methods"},{"key":"3713_CR12","unstructured":"Boyatzis RE. Transforming qualitative information: thematic analysis and code development. sage; 1998."},{"key":"3713_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/nur.1025","volume":"24","author":"M Sandelowski","year":"2001","unstructured":"Sandelowski M. Real qualitative researchers do not count: the use of numbers in qualitative research. Res Nurs Health. 2001;24:230\u201340.","journal-title":"Res Nurs Health"},{"key":"3713_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1136\/bjophthalmol-2018-313669","volume":"103","author":"M Iftikhar","year":"2019","unstructured":"Iftikhar M, Lemus M, Usmani B, Campochiaro PA, Sahel JA, Scholl HPN, Shah SMA. Classification of disease severity in retinitis pigmentosa. Br J Ophthalmol. 2019;103:1595.","journal-title":"Br J Ophthalmol"},{"key":"3713_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12886-015-0081-4","volume":"15","author":"H Guo","year":"2015","unstructured":"Guo H, Li J, Gao F, Li J, Wu X, Liu Q. Whole-exome sequencing reveals a novel CHM gene mutation in a family with choroideremia initially diagnosed as retinitis pigmentosa. BMC Ophthalmol. 2015;15:85.","journal-title":"BMC Ophthalmol"},{"key":"3713_CR16","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.3346\/jkms.2022.37.e5","volume":"37","author":"JH Kim","year":"2022","unstructured":"Kim JH, Han JW, Choi EW, Bang JH, Shin HJ, Jang MA, Lee JY, Choi JN, Chang HS, Park TK. Clinical manifestations and genetic analysis of 5 Korean choroideremia patients initially diagnosed with retinitis pigmentosa. J Korean Med Sci. 2022;37:e5.","journal-title":"J Korean Med Sci"},{"key":"3713_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/IIO.0000000000000385","volume":"61","author":"BL Lam","year":"2021","unstructured":"Lam BL, Davis JL, Gregori NZ. Choroideremia gene therapy. Int Ophthalmol Clin. 2021;61:185\u201393.","journal-title":"Int Ophthalmol Clin"},{"key":"3713_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/13816810.2018.1430242","volume":"39","author":"A Nanda","year":"2018","unstructured":"Nanda A, Salvetti AP, de la Martinez-Fernandez C, MacLaren RE. Misdiagnosis of X-linked retinitis pigmentosa in a choroideremia patient with heavily pigmented fundi. Ophthalmic Genet. 2018;39:380\u20133.","journal-title":"Ophthalmic Genet"},{"key":"3713_CR19","first-page":"1721","volume":"11","author":"J Yang","year":"2018","unstructured":"Yang J, Wang LN, Yu RG, Hu LY, Gong X, Chen L, Hu BJ, Li XR, Li ZQ. Multimodal imaging of the carriers of choroideremia and X-linked retinitis pigmentosa. Int J Ophthalmol. 2018;11:1721\u20135.","journal-title":"Int J Ophthalmol"},{"key":"3713_CR20","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.2147\/OPTH.S65732","volume":"9","author":"MS Zinkernagel","year":"2015","unstructured":"Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. Clin Ophthalmol (Auckland NZ). 2015;9:2195\u2013200.","journal-title":"Clin Ophthalmol (Auckland NZ)"},{"key":"3713_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1020909529486","volume":"36","author":"H Boeije","year":"2002","unstructured":"Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quantity. 2002;36:391\u2013409.","journal-title":"Qual Quantity"},{"key":"3713_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/pajo.pajo_120_21","volume":"4","author":"A Nouraeinejad","year":"2022","unstructured":"Nouraeinejad A. How to make a differential diagnosis between choroideremia and retinitis pigmentosa. Pan-American J Ophthalmol. 2022;4:8\u20138.","journal-title":"Pan-American J Ophthalmol"},{"key":"3713_CR23","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1007\/s12325-020-01275-4","volume":"37","author":"J Green","year":"2020","unstructured":"Green J, Tolley C, Bentley S, et al. Qualitative interviews to better understand the patient experience and evaluate patient-Reported outcomes (PRO) in RLBP1 retinitis pigmentosa (RLBP1 RP). Adv Therapy. 2020;37:2884\u2013901.","journal-title":"Adv Therapy"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03713-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:12:44Z","timestamp":1757362364000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03713-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03713-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided signed informed consent forms for participation in the present study. Ethics approval was obtained from the \u201ccomit\u00e9 de protection des personnes sud-ouest et outre-mer 2\u201d (IRB tracking number 2-20-123 id10393).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The informed consent, signed by each participant, included information about potential publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Elke Rometsch, No\u00e9mie Hurst, Eckhart Eule, Isabel Bachmeier and Per-Olof Thuresson were employees of F. Hoffmann-La Roche at the time of study conduct. Isabelle Audo is a consultant for Novartis and Janssen. Jos\u00e9-Alain Sahel is a consultant\/contractor of Avista Therapeutics and Tenpoint, holds stocks or stock options of GenSight Biologics, Sparing Vision, Prophesee, Chronolife, Tilak Healthcare, VegaVect, Inc., Avista, Tenpoint, SharpEye, Celanese and Netramind, is a member of the scientific advisory board of the Gilbert Foundation, Foundation Fighting Blindness, Institute of Ophthalmology Basel, and Senses Institute Lausanne, and holds patents for Allotopic Expression, Rod-derived Cone Viability Factor and related patents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}